廖伟科博士，1986年7月出生。耀世主管官网副教授，青年博士研究生导师、硕士研究生导师。
联系方式：liaoweike2009@126.com
【学习及工作经历】
2016.08-至今 耀世主管官网
2015.07-2016.07 福建省微生物研究所
2010.09-2015.07 沈阳药科大学 药物化学 博士学位
2006.09-2010.07 沈阳药科大学 药物制剂 学士学位
【研究领域】
主要围绕肿瘤等复杂性疾病的重大临床需求，开展合理的药物设计，为克服临床上应用激酶抑制剂后所产生的获得性耐药提供候选分子。此外，针对现有上市的抗肿瘤药物所存在的不足进行有针对性的改进，为实现肿瘤病人的精准治疗提供一定的物质基础。
【代表性成果】
1. 科研项目：
(1) 贵州省科技支撑计划, MET-TKI在非小细胞肺癌获得性耐药上的机制探索及药物研究，2025-04 至 2028-04，在研，项目实施人;
(2) 国家自然科学基金, 22367006, 靶向正构或变构位点的选择性PI3Kα抑制剂的设计、合成及抗肿瘤活性评价, 2024-01 至 2027-12, 在研, 主持；
(3) 贵州省科技计划项目，基于“共价修饰策略”的选择性PI3Kα抑制剂的设计合成及抗肿瘤活性研究，2024-04 至 2027-04，在研，主持;
(4) 国家自然科学基金, 81903472, 基于吡啶/嘧啶母核的c-Met抑制剂的设计、合成及抗肿瘤活性评价, 2020-01 至 2022-12，已结题, 主持；
(5) 贵州省科技支撑计划, 黔科合支撑2019[2761]号, 利格列汀衍生物LGT-6成药性研究, 2019-01 至 2021-12, 已结题, 主持；
2. 近五年代表性论文：
(1) Shengfei Wua,1, Pengjuan Zhaoa,1, Youli Houa,1,Lihong Hea,1, Zhongyuan Wangc, Dan Yangd, Lijie Simae, Aihong Lia, Xing Cuia, Dongsheng Zhaoa, Bilan Luof, Jianta Wanga, Lan Liub***, Weike Liao**, Yu Zhang*. Design, synthesis, and biological evaluation of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry, 2025, 289: 117492. (IF = 6.0).
(2) Beijing Chen1, Zhongyuan Wang1, Qi Chen1, Ying Zhang1, Yu Zhang, Aihong Li, Shengfei Wu, Weiwei Ouyang, Lijie Sima, Xiaoxu Li, Dongsheng Zhao, Bilan Luo, Jianta Wang, Lei Tang*, Xiaoming Su*, Weike Liao*. Discovery of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry, 2025, 283:117173. (IF = 6.0).
(3) Junyan Zhuang#, Renming Fan#, Weike Liao#, Ruizhuo Lin, Aohua Deng, Ting Zhao, Yongrui Hai, Heran Li, Lei Tang*, Gaofei Wei*. Organelle Synergy Unleashed: Modulating Mitochondrial Endoplasmic Reticulum Contacts with a Self-Assembled Prodrug Amplifies Ferroptosis for Innovative Cancer Therapy. Chemical Engineering Journal, 2024, 495: 153364. Co-first author. (IF = 13.3).
(4). Tingting Wu1, Hu Cheng1, Lijie Sima1, ZhongyuanWang, Weiwei Ouyang, Jianta Wang, Yunlei Hou, Dongsheng Zhao*, Weike Liao*, Chujiao Hu*. Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterization. Journal of Enzyme Inhibition and Medicinal Chemistry, 2024, 39(1): 2353711. (IF = 5.6).
(5) Rui Chen; Zhongyuan Wang; Lijie Sima; Hu Cheng; Bilan Luo; Jianta Wang; Bing Guo; Shunyi Mao; Zhixu Zhou; Jingang Peng; Lei Tang; Xinfu Liu*; Weike Liao*; Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3Kα inhibitors, Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38(1): 2155638. (IF = 5.6).
(6) Weike Liao1, Yu Zhang1, Zhixu Zhou, Xing Cui, Jianta Wang, Zhongyuan Wang∗,
Lei Tang*. Synthesis, structural analysis, vibrational properties, and chiral separation of Xanthine-Quinazoline diastereomers, Journal of Molecular Structure, 2022, 1253: 132311. (IF = 4.0).
(7) Weike Liao; Zhongyuan Wang; Yufei Han; Yinliang Qi; Jiaan Liu; Juan Xie; Ye Tian; Qiancheng Lei; Rui Chen; Ming Sun; Lei Tang; Guowei Gong; Yanfang Zhao; Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity, European Journal of Medicinal Chemistry, 2020, 197: 112309. (IF = 6.7).
